Additional health claims approved for Lallemand probiotic


These three claims are an addition to the previously approved indication in the irritable bowel syndrome area

Lallemand Health Solutions has gained indications for its documented Expert’Biotic IBacilluS+ (a combination of probiotic strain Enterococcus faecium Rosell-26 and Bacillus subtilis Rosell-179) on Reflux Esophagitis (RE) and Small Intestine Bacterial Overgrowth (SIBO) following proton pump inhibitor treatment.

The new Canadian health claims for IBacilluS+ are: Helps reduce the reappearance of reflux esophagitis symptoms following proton pump inhibitor treatment; helps extend time between reappearance of reflux esophagitis symptoms following proton pump inhibitor treatment; helps reduce the risk of Small Intestine Bacterial Overgrowth after proton pump inhibitor treatment.

“These new claims are a big regulatory achievement for our organisation”, said Solange Henoud, Global Regulatory Affairs Director. “Especially considering the innovative applications they bring on the market. We are now able to provide probiotic solutions to support people living with Reflux Esophagitis and Small Intestine Bacterial Overgrowth inconveniences; PPI treatments are administered way more commonly than we think; we are glad to bring in such an approved natural health supportive intervention.”

These claims are supported by a recent clinical study (Sun, 2019), investigating the effect of IBacilluS+ taken in concomitance with esomeprazole (PPIs) vs. the intake of placebo with esomeprazole in 130 adults with RE. IBacilluS+ significantly extended time between reappearance of RE over the follow-up period and reduced SIBO against the placebo group. These results have been confirmed in the Shi study in 2020, showing how IBacilluS+ significantly decreased SIBO rate and helped balance individuals’ microflora in people with gut disturbances or SIBO, in comparison to the placebo group.

IBacilluS+ is a documented combination of two probiotic strains Enterococcus faecium Rosell- 26 and Bacillus subtilis Rosell-179.


Sun et al., 2019. Beneficial effect of probiotics supplements in reflux esophagitis treated with esomeprazole: A randomized controlled trial, World J Gastroenterol 2019 7; 25(17): 2110-2121.

Sign up for your free email newsletter

Shi et al., 2020. Effect of Combined Live Probiotics Alleviating the Gastrointestinal Symptoms of Functional Bowel Disorders, Gastroenterology Research and Practice Volume 2020, Article ID 4181748, 11 pages

Features Companies